Title: The Critical Role of Vascular Endothelial Growth Factor in Tumor Angiogenesis
Volume: 12
Issue: 1
Author(s): A. Amini, S. Masoumi Moghaddam, D. L. Morris and M. H. Pourgholami
Affiliation:
Keywords:
Angiogenesis, bevacizumab, hypoxia-inducible factor, pazopanib, ranibizumab, sorafenib, vascular endothelial growth factor, tumor angiogenesis, epidermal growth factor, colony stimulating factor, Food and Drug Association, objective response rate, kinase domain region
Abstract: Angiogenesis is the formation of new blood vessels from the pre-existing vasculature. Besides its role in normal physiology, angiogenesis is significantly involved in many pathological conditions, including inflammation, cardiovascular diseases and cancer. Numerous studies have been undertaken in the area of tumor angiogenesis. It is known that pathological angiogenesis is necessary for tumors to proceed from avascular, dormant stage to vascular, sprouting stage and also contributes to their later invasion and metastasis. Playing a central role in tumor angiogenesis, vascular endothelial growth factor is considered as a key target in therapeutic approaches. This article aims to review the critical role of VEGF in tumor angiogenesis and the importance of VEGF-targeted strategies in cancer treatment.
